Trial Profile

A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifamycin (Primary)
Indications Blind loop syndrome
Focus Therapeutic Use

Most Recent Events

03 Apr 2025 Results assessing the o evaluate the efficacy of two different dosing regimens (twice daily and three times daily) of rifamycin SV MMX (AEMCOLO) in the treatment of small intestinal bacterial overgrowth (SIBO) were published in the BMC Gastroenterology.
29 Apr 2022 Planned number of patients changed from 60 to 30.
29 Apr 2022 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com